Received: 10-09-2025

Accepted: 20-09-2025

Published: 29-09-2025

Citation: Abhijit Trailokya (2025) Cagrilintide-Semaglutide (CagriSema): A Novel Combination Therapy for Obesity and Type 2 Diabetes Mellitus – Results from REDEFINE 1 and REDEFINE 2. Diab Obes Metab Disor OA, 11(11): 1-2.

Copyrights: ©2025 Abhijit Trailokya. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.